

Serial No. 09/834,229

compound is a "peptide" which interacts with the GLP-1 receptor. Applicants respectfully request that the Examiner consider amended Claims 20 and 21 with Claims 13 through 19.

The above-referenced application is a continuation of issued U.S. Patent No. 6,277,819. The Examiner in that case is the same examiner of record in this case. Because the parent case was examined extensively and Claims 13 through 19 are not broader with respect to the genus of compounds specified, Applicants submit it would not be an undue burden for the examiner to additionally consider claims 20 and 21 that encompass peptide agonists of the GLP-1 receptor in this Application. Thus, Applicants request that Claims 13 through 19 be examined with amended Claims 20 and 21.

Respectfully submitted,



Mark J. Stewart
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

November 27, 2002

Attachment A

Marked-up copy of amendments as required by 37 C.F.R. § 1.121

20. (amended) A method of reducing morbidity and mortality after myocardial infarction comprising administering to a patient in need thereof a [compound] peptide that exerts insulintropic activity by interacting with the same receptor or receptors with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in exerting their insulintropic activity at a dose effective to normalize blood glucose.

21. (amended) A method of reducing morbidity and mortality after myocardial infarction comprising administering to a patient in need thereof a [compound] peptide that enhances insulin sensitivity by interacting with the same receptor or receptors with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in enhancing insulin sensitivity at a dose effective to normalize blood glucose.